Method for preparing zalvizepam chiral intermediate by chemical-enzyme method
Through chemical-enzyme method, Compound II reacted with nitrite reagent and acrylate, combined with phenylalanine aminolyzase catalyzed, the high-purity and high yield of Zavejipan chiral intermediate I was successfully prepared, and the current solution was solved There are problems of long routes and low yields in the technology, which achieves simple operation and suitable for industrial production.
Patent Information
- Application Number
- CN202310618170.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the preparation method of Zavejipan chiral intermediate compound I has a long route and low yield. The assembly of chiral amino acids and indazole rings is challenging, and it is necessary to develop simple operation, short steps, low cost, and yield. High selectivity preparation method.
Using chemical-enzymatic method, compound II reacts with nitrite reagent to form compound III, and then is coupled with acrylate under the action of Pd catalyst to form compound IV, which is catalyzed by phenylalanine aminolyzase and is finally converted to compound V through methyl ester. The synthesis reaction gave compound I.
The preparation of the high-purity and high yield of Zavijipan chiral intermediate I was achieved, with high economical reaction atoms, a single enzyme, short route, and suitable for industrial production.
Smart Images

Figure BDA0004254570340000011 
Figure BDA0004254570340000021 
Figure BDA0004254570340000031
Abstract
Description
Technical field:
[0001] The invention belongs to the technical field of biocatalysis, and in particular relates to a method for preparing a zavidhipan chiral intermediate by a chemical-enzymatic method. Background technology:
[0002] Zavegepant was developed by Bristol-Myers Squibb and launched in the United States on March 9, 2023 under the trade name Zavzpret. It is mainly used to treat acute migraine with or without aura in adults. Its chemical structure is shown below:
[0003]
[0004] In 2011, Bristol-Myers Squibb Company disclosed a method for preparing zavidipam in patent CN102834388B, and the route is shown in Scheme 1. This method uses compounds 1 and 3 as starting materials, and obtains compounds 2 and 4 through iodination and methanesulfonylation / elimination reactions respectively, and then reacts under the action of palladium acetate to obtain compound 5, and then constructs a chiral center under the catalytic action of catalyst [(2R,5R)-Et-DuPhosRh]BF4 to generate compound 6, and finally compound 6 reacts with isopentyl nitrite to construct an indazole ring, and Pd / C hydrogenation removes the CBZ protecting group to complete the preparation of the free compound I', with a total yield of 43%. Subsequently, compound I undergoes multiple steps of reaction to obtain zavidipam.
[0005]
[0006] It can be seen from the route disclosed by the original research company that compound I is the key chiral intermediate for the preparation of zavirigopam.
[0007] In 2012, Bristol-Myers Squibb Company disclosed an improved process for compound I in the document Organic Process Research & Development, 2012, 16 (12), 1953-1966. The route is shown in Scheme 2. The process uses enzyme catalysis to construct the chiral center, using compound 8 as the starting material, and obtaining compound 12 through four steps of reaction. Compound 12 is then converted into compound 13 under the action of D-aminotransferase, and finally compound I is obtained through methyl esterification reaction, with a total yield of less than 40%.
[0008]
[0009] In 2022, patent WO2022172829A1 disclosed a method for preparing compound I by multi-enzyme catalysis, as shown in Scheme 3. In this method, compound 10 undergoes a two-step reaction to obtain an enzymatic substrate compound 15, which is then hydrolyzed under the action of hydantoinase, decarbamylase, hydantoin racemase, etc. to produce compound 13, and finally undergoes a methylation reaction to produce compound I. This reaction involves three enzymes, requires a large amount of cells, and has a low overall yield.
[0010]
[0011] In the prior art, the preparation method of compound I has a long route, low yield, and the assembly of chiral amino acids and indazole rings is very challenging. Therefore, we need to develop a preparation method with simple operation, short steps, low cost, high yield and selectivity. Summary of the invention:
[0012] The purpose of the present invention is to provide a method for preparing a chiral intermediate I of zavirigopam which is simple to operate and easy to industrialize in view of the deficiencies in the prior art.
[0013] In one aspect, the present invention provides a novel compound, a compound having a structure as shown in Formula IV, or a pharmaceutically acceptable salt thereof,
[0014]
[0015] On the other hand, the present invention provides a method for preparing a chiral intermediate of zavirigopam (Compound I), and its technical scheme is shown in Scheme 4.
[0016] The technical solution adopted by the present invention is as follows:
[0017]
[0018] The invention provides a method for preparing a zavidigpan chiral intermediate I by a chemical-enzymatic method, which specifically comprises the following steps: compound II reacts with a nitrous acid reagent to obtain compound III, compound III and acrylate undergo a coupling reaction under the action of a Pd catalyst to generate compound IV, compound IV is converted into compound V under the action of phenylalanine ammonia lyase, and finally compound V undergoes a methyl esterification reaction to generate compound I.
[0019] Furthermore, the nitrous acid reagent is selected from isoamyl nitrite and tert-butyl nitrite, preferably isoamyl nitrite.
[0020] Furthermore, the acrylic acid ester is selected from acrylic acid C1-C6 saturated or unsaturated hydrocarbon esters and benzyl esters.
[0021] Furthermore, the acrylic acid ester is selected from methyl acrylate, ethyl acrylate, propyl acrylate, isopropyl acrylate, butyl acrylate, vinyl acrylate, benzyl acrylate, preferably isopropyl acrylate.
[0022] Furthermore, the coupling reaction catalyst is a palladium catalyst, and the palladium catalyst is selected from PdCl2(dppf) and Pd(PPh3)4.
[0023] Furthermore, the phenylalanine ammonia lyase is derived from Vibrio vulnificus.
[0024] Furthermore, the phenylalanine ammonia lyase participates in the catalytic reaction in the form of phenylalanine ammonia lyase powder, phenylalanine ammonia lyase liquid, cells containing phenylalanine ammonia lyase, etc.
[0025] Furthermore, the phenylalanine ammonia lyase is selected from ES-PAL-101 to ES-PAL-110 produced by Shangke Biopharmaceutical (Shanghai) Co., Ltd.
[0026] The beneficial effect of the present invention is that the present invention discloses a new chemical-enzymatic method for preparing a chiral intermediate I of zawigipan, wherein the method uses compound II as a starting material, performs a two-step reaction to prepare a new compound IV, then obtains compound V under the action of phenylalanine ammonia lyase, and finally methylates to obtain compound I. The enzymatic reaction has high atom economy, uses a single enzyme, has a short route, a high yield, is simple to operate, and is easy to industrialize. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] none DETAILED DESCRIPTION
[0028] The technical content of the present invention is further described below in conjunction with specific embodiments, the purpose of which is to provide a better understanding of the content of the present invention, but the protection scope of the present invention is not limited thereto.
[0029] Example 1 Preparation of Compound III
[0030] Compound II (24.71 g, 0.1 mol, 1.0 eq), 65 mL of glacial acetic acid, 1.0 L of toluene, and potassium acetate (58.9 g, 0.6 mol, 6.0 eq) were added to a 2L three-necked flask in sequence. Isoamyl nitrite (12.9 g, 0.11 mol, 1.1 eq) was slowly added to the system at 20-25°C, and the reaction was completed by stirring for 24 hours. Saturated sodium carbonate was added to the reaction system to adjust the pH to 7-8, the organic phase was washed with 1 L of water, the aqueous phase was extracted with 1 L of dichloromethane, the organic phases were combined and concentrated under reduced pressure, 60 mL of ethyl acetate was added, heated to 70°C to dissolve, seed crystals were added, the temperature was lowered to 25°C, 150 mL of n-heptane was added, stirred overnight, filtered, the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45°C to obtain 21.16 g of compound III with a purity of 97.5% and a yield of 82%.
[0031] Example 2 Preparation of Compound III
[0032] Compound II (24.71 g, 0.1 mol, 1.0 eq), 65 mL of glacial acetic acid, 1.0 L of toluene, and potassium acetate (58.9 g, 0.6 mol, 6.0 eq) were added to a 2L three-necked flask in sequence. Isobutyl nitrite (11.34 g, 0.11 mol, 1.1 eq) was slowly added to the system at 20-25°C, and the reaction was completed by stirring for 24 hours. Saturated sodium carbonate was added to the reaction system to adjust the pH to 7-8, the organic phase was washed with 1 L of water, the aqueous phase was extracted with 1 L of dichloromethane, the organic phases were combined and concentrated under reduced pressure, 60 mL of ethyl acetate was added, heated to 70°C to dissolve, seed crystals were added, the temperature was lowered to 25°C, 150 mL of n-heptane was added, stirred overnight, filtered, the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45°C to obtain 21.16 g of compound III with a purity of 97.9% and a yield of 79.2%.
[0033] Example 3 Preparation of Compound IV
[0034] Under nitrogen protection, compound III (20 g, 77.5 mmol, 1.0 eq), ethyl acrylate (9.7 g, 96.8 mmol, 1.25 eq), N,N-diisopropylethylamine (15 g, 116.3 mmol, 1.5 eq), DMF 200 mL, tetrakis(triphenylphosphine) palladium (0.3 g, 0.23 mmol, 0.003 eq) were added to a 500 mL three-necked flask in sequence, the temperature was raised to 100 ° C, the reaction was stirred for 16 h, the temperature was cooled to room temperature, the solvent was dried, 400 mL of ethyl acetate was added for extraction, the organic phases were combined and concentrated to 80 mL under reduced pressure, the temperature was raised to 60 ° C and then slowly cooled, filtered, the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45 ° C to obtain 14.2 g of solid. To a 250 mL round-bottom flask, 100 mL of ethanol, 40 mL of water, 5.6 g of sodium hydroxide, and 14.2 g of the dried solid were added, and the mixture was stirred at 40 ° C for 5 h. After the reaction, the pH was adjusted to 3-4 with 2N hydrochloric acid, and the ethanol was distilled off. The mixture was filtered and dried in vacuo at 45 ° C to obtain 12.2 g of compound IV with a purity of 98.1% and a yield of 77.9%.
[0035] Example 4 Preparation of Compound IV
[0036] Under nitrogen protection, compound III (20 g, 77.5 mmol, 1.0 eq), isopropyl acrylate (11.05 g, 96.8 mmol, 1.25 eq), N,N-diisopropylethylamine (15 g, 116.3 mmol, 1.5 eq), DMF 200 mL, tetrakis(triphenylphosphine) palladium (0.3 g, 0.23 mmol, 0.003 eq) were added to a 500 mL three-necked flask in sequence, the temperature was raised to 100 ° C, and the reaction was stirred for 16 h. The reaction was completed, cooled to room temperature, the solvent was dried, 400 mL of ethyl acetate was added for extraction, the organic phases were combined and concentrated under reduced pressure to 80 mL, the temperature was raised to 60 ° C and then slowly cooled, filtered, the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45 ° C to obtain 14.2 g of solid. To a 250 mL round-bottom flask, 100 mL of ethanol, 40 mL of water, 5.6 g of sodium hydroxide, and 15.1 g of the dried solid were added, and the mixture was stirred at 40 ° C for 5 h. After the reaction, the pH was adjusted to 3-4 with 2N hydrochloric acid, and the ethanol was distilled off. The mixture was filtered and dried in vacuo at 45 ° C to obtain 12.7 g of compound IV with a purity of 98.3% and a yield of 81.2%.
[0037] Example 5 Preparation of Compound IV
[0038] Under nitrogen protection, compound III (20 g, 77.5 mmol, 1.0 eq), vinyl acrylate (9.5 g, 96.8 mmol, 1.25 eq), N,N-diisopropylethylamine (15 g, 116.3 mmol, 1.5 eq), DMF 200 mL, tetrakis(triphenylphosphine) palladium (0.3 g, 0.23 mmol, 0.003 eq) were added to a 500 mL three-necked flask in sequence, the temperature was raised to 100 ° C, and the reaction was stirred for 16 h. The reaction was completed, cooled to room temperature, the solvent was dried, 400 mL of ethyl acetate was added for extraction, the organic phases were combined and concentrated to 80 mL under reduced pressure, the temperature was raised to 60 ° C and then slowly cooled, filtered, the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45 ° C to obtain 14.2 g of solid. To a 250 mL round-bottom flask, 100 mL of ethanol, 40 mL of water, 5.6 g of sodium hydroxide, and 14.5 g of the dried solid were added, and the mixture was stirred at 40 ° C for 5 h. After the reaction, the pH was adjusted to 3-4 with 2N hydrochloric acid, and the ethanol was distilled off. The mixture was filtered and dried in vacuo at 45 ° C to obtain 12.5 g of compound IV with a purity of 97.8% and a yield of 79.5%.
[0039] Example 6 Preparation of Compound IV
[0040] Under nitrogen protection, compound III (20 g, 77.5 mmol, 1.0 eq), benzyl acrylate (15.7 g, 96.8 mmol, 1.25 eq), N,N-diisopropylethylamine (15 g, 116.3 mmol, 1.5 eq), DMF 200 mL, tetrakis(triphenylphosphine) palladium (0.3 g, 0.23 mmol, 0.003 eq) were added to a 500 mL three-necked flask in sequence, the temperature was raised to 100 ° C, and the reaction was stirred for 16 h. The reaction was completed, cooled to room temperature, the solvent was dried, 400 mL of ethyl acetate was added for extraction, the organic phases were combined and concentrated to 80 mL under reduced pressure, the temperature was raised to 60 ° C and then slowly cooled, filtered, the filter cake was rinsed with 50 mL of ethyl acetate: n-heptane = 1:3, and the filter cake was vacuum dried at 45 ° C to obtain 14.2 g of solid. To a 250 mL round-bottom flask, 100 mL of ethanol, 40 mL of water, 5.6 g of sodium hydroxide, and 19.5 g of the dried solid were added, and the mixture was stirred at 40 ° C for 5 h. After the reaction, the pH was adjusted to 3-4 with 2N hydrochloric acid, and the ethanol was distilled off. The mixture was filtered and dried in vacuo at 60 ° C to obtain 12.0 g of compound IV with a purity of 98.0% and a yield of 77.9%.
[0041] Example 7 Preparation of Compound V
[0042] Compound IV (10 g, 0.05 mol, 1.0 eq), DMSO 20 mL, deionized water 50 mL, solid ammonium chloride (10.70 g, 0.2 mol, 4.0 eq) were added to a 1L three-necked flask in sequence. The pH was adjusted to 7.0 ± 0.2 with concentrated ammonia water. 150 mL of 0.1 M pH 7.0 phosphate buffer and 10 g of phenylalanine ammonia lyase enzyme supernatant (pH = 7.0 ± 0.2) were added. The reaction was carried out at 40 ° C for 36 h. IPC was sampled. The raw material remained about 5%. The reaction solution was filtered, hydrochloric acid was added to the filtrate to adjust the pH to 3-4, ethyl acetate (100 mL * 2) was extracted twice, and the aqueous phase was distilled until 150 mL remained. A large amount of solid precipitated. The temperature was lowered and filtered. 8.2 g of compound I was obtained at 50 ° C in a vacuum dryer with a purity of 98.5%, a yield of 75.6%, and a chiral purity of 99.6%.
[0043] Example 8 Preparation of Compound I
[0044] In a 250mL three-necked flask, add 150mL of methanol and compound V (8.0g, 36mmol, 1.0eq) in sequence, raise the temperature to 45-55°C, slowly add dichlorothionyl (13.0g, 109mmol, 3.0eq), continue stirring for 15h after the addition is complete, cool to room temperature, filter, rinse the filter cake with 20mL of methanol, and dry in vacuo at 50°C to obtain 10.2g of solid with a purity of 99.1%, a yield of 91.3%, and a chiral purity of 99.6%.
Claims
1. A method for preparing a chiral intermediate compound I of zavigipan by chemical-enzymatic method, characterized in that: The method comprises the following steps: compound II reacts with a nitrous acid reagent to obtain compound III; compound III then undergoes a coupling reaction with acrylate under the action of a Pd catalyst to generate compound IV; compound IV is converted into compound V under the action of phenylalanine ammonia lyase; and compound V undergoes a methyl esterification reaction to generate compound I.
2. The preparation method according to claim 1, characterized in that The nitrous acid reagent is selected from isoamyl nitrite and tert-butyl nitrite.
3. The preparation method according to claim 1, characterized in that: The acrylic acid ester is selected from C1-C6 saturated or unsaturated hydrocarbon esters and benzyl esters of acrylic acid.
4. The preparation method according to claim 1, characterized in that: The Pd catalyst is selected from PdCl2(dppf) and Pd(PPh3)4.
5. The preparation method according to claim 1, characterized in that: The phenylalanine ammonia lyase is derived from Vibriovulnificus.
6. A compound of formula IV, or a pharmaceutically acceptable salt thereof, 7. Compound IV according to claim 6, characterized in that The compound IV can be used to prepare the chiral intermediate compound I of zavirigepam.
Citation Information
Cited By
Preparation method of zavazepam chiral indazole intermediate
CN121950959A
